Subscribe

Apeloa Pharmaceutical Co.,Ltd (000739.SZ)

CNY20.47 +1.38 (+7.23%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address No. 333, Jiangnan Road 322118
Dongyang, CN
CEO Fangmeng Zhu
Website apeloa.com
IPO 1997-05-09
ISIN CNE000000Q45

Explore sections of this company profile

Description

Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY20.47 +1.38 (+7.23%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
12M
Beta
0.30
Float Shares
1.10B
Free Float %
94.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.54% -2.87% -10.07% -8.08% +3.81% +2.09% +19.32% -14.20% -36.31% +176.37% +931.68%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
20.47
DCF (Unlevered) 34.55 +68.8%
DCF (Levered) 23.05 +12.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 2 0
Buy 3 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.94
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -18.8% Q1'26: -10.4% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -13.5% Q1'26: +4.8% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +5.8% Q1'26: +0.6% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +9.0% Q1'26: +13.0% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +18.0% ★ Q1'26: +18.1% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    -0.5% ★ Q1'26: -3.7% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.97× ★ Q1'26: 2.33× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.34) × ERP
WACC = 93% × Ke + 7% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 34.86 Current price: 20.47
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
5 Rev. Ana.
1 EPS Ana. 		Dec 2027
5 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
4.34B
est: 4.59B (-5.6%)
4.77B
est: 4.72B (+1.2%)
5.55B
est: 5.87B (-5.4%)
6.38B
est: 6.40B (-0.4%)
7.21B
est: 7.48B (-3.5%)
7.88B
est: 8.09B (-2.6%)
8.94B
est: 9.05B (-1.1%)
10.54B
est: 10.47B (+0.8%)
11.47B
est: 11.99B (-4.3%)
12.02B
est: 12.59B (-4.5%)
9.76B
est: 10.41B (-6.2%)
10.46B
9.68B – 10.98B
+0.5% YoY
11.46B
10.34B – 12.40B
+9.5% YoY
12.75B
11.65B – 13.60B
+11.3% YoY
EBITDA
531.55M
est: 635.54M (-16.4%)
576.51M
est: 652.41M (-11.6%)
704.68M
est: 812.03M (-13.2%)
749.99M
est: 885.93M (-15.3%)
957.00M
est: 1.03B (-7.5%)
1.17B
est: 1.12B (+4.3%)
1.32B
est: 1.25B (+5.3%)
1.30B
est: 1.45B (-10.5%)
1.63B
est: 1.66B (-1.6%)
1.58B
est: 1.77B (-11.0%)
1.56B
est: 1.46B (+6.4%)
1.47B
1.36B – 1.54B
+0.5% YoY
1.61B
1.45B – 1.74B
+9.5% YoY
1.79B
1.64B – 1.91B
+11.3% YoY
EBIT
245.31M
est: 437.25M (-43.9%)
274.96M
est: 448.86M (-38.7%)
373.05M
est: 558.68M (-33.2%)
420.59M
est: 609.52M (-31.0%)
603.45M
est: 711.46M (-15.2%)
823.59M
est: 770.21M (+6.9%)
959.39M
est: 860.96M (+11.4%)
906.80M
est: 996.09M (-9.0%)
1.08B
est: 1.14B (-5.5%)
1.01B
est: 1.16B (-12.9%)
878.92M
est: 960.60M (-8.5%)
965.76M
892.95M – 1.01B
+0.5% YoY
1.06B
954.57M – 1.14B
+9.5% YoY
1.18B
1.07B – 1.26B
+11.3% YoY
Net Income
208.23M
est: 324.36M (-35.8%)
262.90M
est: 231.69M (+13.5%)
256.59M
est: 359.12M (-28.5%)
370.56M
est: 385.76M (-3.9%)
553.40M
est: 557.59M (-0.8%)
816.73M
est: 784.27M (+4.1%)
955.55M
est: 1.03B (-7.5%)
989.17M
est: 960.85M (+2.9%)
1.06B
est: 1.19B (-11.6%)
1.03B
est: 1.13B (-8.8%)
890.68M
est: 932.23M (-4.5%)
1.06B
940.32M – 1.15B
+13.7% YoY
1.26B
1.12B – 1.37B
+18.7% YoY
1.52B
1.35B – 1.65B
+21.0% YoY
SGA
853.11M
est: 464.43M (+83.7%)
953.12M
est: 476.76M (+99.9%)
983.64M
est: 593.40M (+65.8%)
1.26B
est: 647.41M (+95.3%)
1.29B
est: 755.68M (+70.6%)
953.28M
est: 818.09M (+16.5%)
895.92M
est: 914.47M (-2.0%)
980.68M
est: 1.06B (-7.3%)
1.12B
est: 1.21B (-7.2%)
1.12B
est: 1.19B (-6.1%)
872.90M
est: 986.63M (-11.5%)
991.93M
917.14M – 1.04B
+0.5% YoY
1.09B
980.43M – 1.18B
+9.5% YoY
1.21B
1.10B – 1.29B
+11.3% YoY
EPS
0.18
est: 0.28 (-35.7%)
0.23
est: 0.20 (+15.0%)
0.22
est: 0.31 (-29.0%)
0.31
est: 0.33 (-6.9%)
0.47
est: 0.48 (-2.4%)
0.69
est: 0.68 (+1.9%)
0.81
est: 0.89 (-9.2%)
0.85
est: 0.83 (+2.5%)
0.90
est: 1.03 (-12.6%)
0.89
est: 0.98 (-9.2%)
0.77
est: 0.81 (-4.7%)
0.92
0.82 – 1.00
+13.7% YoY
1.09
0.97 – 1.19
+18.7% YoY
1.32
1.17 – 1.43
+21.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-28 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-27 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-26 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-25 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-22 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-21 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-20 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-19 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-18 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-15 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-14 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-13 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-12 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-11 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-08 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-07 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-05-06 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-04-30 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-29 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-28 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-27 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-24 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-23 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-22 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-21 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-20 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-17 A- 4/5 4/5 4/5 5/5 1/5 3/5 3/5
2026-04-16 A- 4/5 4/5 4/5 5/5 1/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
357.30M
OE per share TTM
0.31
Owner's Yield
1.91%
Maintenance CapEx ratio
78.96%
Maint CapEx / Avg PPE
30.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 34 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS 0.10% 36.9K 0.65%
2 State Street SPDR S&P Emerging Asia Pacific ETF GMF 0.01% 63.0K 0.49%
3 Franklin FTSE China ETF FLCH 0.01% 35.1K 0.19%
4 Franklin FTSE China UCITS ETF FLXC.L 0.01% 153.1K 0.19%
5 Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR 0.01% 5.5K 0.15%
6 State Street SPDR Portfolio Emerging Markets ETF SPEM 0.01% 1.62M 0.07%
7 Dimensional - Emerging Markets High Profitability ETF DEHP 0.01% 39.9K 0.44%
8 iShares International Dividend Growth ETF IGRO 0.01% 80.1K 0.15%
9 Vanguard International Dividend Appreciation ETF VIGI 0.00% 437.9K 0.07%
10 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 323.2K 0.39%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
124.5K
Shares Outstanding
1.16B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Chun He President & Head of ACI BU — male
Fangmeng Zhu CEO & Chairman — male
Hui Zhang Chief Technology Officer — male
Jinhui Zhang Chief Financial Officer — male
Lei Cai Senior Vice President & Head of CDMO BU — male
Liang Yu Head of FDF BU — male
Lihua Wu Chief Financial Officer — male
Min Jin Senior Vice President — male
Xinliang Xu Vice Chairman — male
Yonglong Li Head of API BU — male
Yuwang Zhou Vice President & Secretary — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic